Immunogen (IMGN) Tops Q2 EPS by 3c

Immunogen (NASDAQ: IMGN) reported Q2 EPS of ($0.14), $0.03 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $15 million versus the consensus estimate of $14.59 million.

GUIDANCE:

Immunogen sees FY2020 revenue of $60-65 million, versus the consensus of $63.1 million.

• operating expenses between $165 million and $170 million; and
• cash and cash equivalents at December 31, 2020 to be between $170 million and $175 million.

For earnings history and earnings-related data on Immunogen (IMGN) click here.

You May Also Be Interested In

• Freightos Limited (CRGO) Tops Q2 EPS by 3c ; Offers Guidance
• Laser Photonics Corporation (LASE) Reports Q2 Loss of $0.08
• Paramount Global (PARA) Tops Q2 EPS by 480c